PURPOSE: Aberrant promoter hypermethylation of several known or putative tumor suppressor genes occurs frequently during the pathogenesis of various cancers including breast cancer. Many epigenetically inactivated genes involved in breast cancer development remain to be identified. Therefore, in this study we used a pharmacologic unmasking approach in breast cancer cell lines with 5-aza-2'-deoxycytidine (5-aza-dC) followed by microarray expression analysis to identify epigenetically inactivated genes in breast cancer. EXPERIMENTAL DESIGN: Breast cancer cell lines were treated with 5-aza-dC followed by microarray analysis to identify epigenetically inactivated genes in breast cancer. We then used bisulfite DNA sequencing, conventional methylation-specific PCR, and quantitative fluorogenic real-time methylation-specific PCR to confirm cancer-specific methylation in novel genes. RESULTS: Forty-nine genes were up-regulated in breast cancer cells lines after 5-aza-dC treatment, as determined by microarray analysis. Five genes (MAL, FKBP4, VGF, OGDHL, and KIF1A) showed cancer-specific methylation in breast tissues. Methylation of at least two was found at high frequency only in breast cancers (40 of 40) as compared with normal breast tissue (0 of 10; P<0.0001, Fisher's exact test). CONCLUSIONS: This study identified new cancer-specific methylated genes to help elucidate the biology of breast cancer and as candidate diagnostic markers for the disease.
PURPOSE: Aberrant promoter hypermethylation of several known or putative tumor suppressor genes occurs frequently during the pathogenesis of various cancers including breast cancer. Many epigenetically inactivated genes involved in breast cancer development remain to be identified. Therefore, in this study we used a pharmacologic unmasking approach in breast cancer cell lines with 5-aza-2'-deoxycytidine (5-aza-dC) followed by microarray expression analysis to identify epigenetically inactivated genes in breast cancer. EXPERIMENTAL DESIGN:Breast cancer cell lines were treated with 5-aza-dC followed by microarray analysis to identify epigenetically inactivated genes in breast cancer. We then used bisulfite DNA sequencing, conventional methylation-specific PCR, and quantitative fluorogenic real-time methylation-specific PCR to confirm cancer-specific methylation in novel genes. RESULTS: Forty-nine genes were up-regulated in breast cancer cells lines after 5-aza-dC treatment, as determined by microarray analysis. Five genes (MAL, FKBP4, VGF, OGDHL, and KIF1A) showed cancer-specific methylation in breast tissues. Methylation of at least two was found at high frequency only in breast cancers (40 of 40) as compared with normal breast tissue (0 of 10; P<0.0001, Fisher's exact test). CONCLUSIONS: This study identified new cancer-specific methylated genes to help elucidate the biology of breast cancer and as candidate diagnostic markers for the disease.
Authors: James Hamill; Ian D Campbell; Frederick Mayall; Adam St J R Bartlett; Ann Darlington Journal: Acta Cytol Date: 2002 Jan-Feb Impact factor: 2.319
Authors: Yutaka Tokumaru; Susan V Harden; Dong-Il Sun; Keishi Yamashita; Jonathan I Epstein; David Sidransky Journal: Clin Cancer Res Date: 2004-08-15 Impact factor: 12.531
Authors: Mohammad Obaidul Hoque; Chyi-Chia R Lee; Paul Cairns; Mark Schoenberg; David Sidransky Journal: Cancer Res Date: 2003-05-01 Impact factor: 12.701
Authors: Rachel Krassenstein; Edward Sauter; Essel Dulaimi; Cristina Battagli; Hormoz Ehya; Andres Klein-Szanto; Paul Cairns Journal: Clin Cancer Res Date: 2004-01-01 Impact factor: 12.531
Authors: Yutaka Tokumaru; Keishi Yamashita; Motonobu Osada; Shuji Nomoto; Dong-Il Sun; Yan Xiao; Mohammad Obaidul Hoque; William H Westra; Joseph A Califano; David Sidransky Journal: Cancer Res Date: 2004-09-01 Impact factor: 12.701
Authors: Mohammad Obaidul Hoque; Myoung Sook Kim; Kimberly Laskie Ostrow; Junwei Liu; G Bea A Wisman; Hannah Lui Park; Maria Luana Poeta; Carmen Jeronimo; Rui Henrique; Agnes Lendvai; Ed Schuuring; Shahnaz Begum; Eli Rosenbaum; Maté Ongenaert; Keishi Yamashita; Joseph Califano; William Westra; Ate G J van der Zee; Wim Van Criekinge; David Sidransky Journal: Cancer Res Date: 2008-04-15 Impact factor: 12.701
Authors: Rebecca L Fagan; Diane E Cryderman; Levy Kopelovich; Lori L Wallrath; Charles Brenner Journal: J Biol Chem Date: 2013-07-09 Impact factor: 5.157
Authors: Myriam Loyo; Mariana Brait; Myoung S Kim; Kimberly L Ostrow; Chunfa C Jie; Alice Y Chuang; Joseph A Califano; Nanette J Liégeois; Shahnaz Begum; William H Westra; Mohammad O Hoque; Qian Tao; David Sidransky Journal: Int J Cancer Date: 2011-03-15 Impact factor: 7.396
Authors: Alessandro Bartolomucci; Roberta Possenti; Sushil K Mahata; Reiner Fischer-Colbrie; Y Peng Loh; Stephen R J Salton Journal: Endocr Rev Date: 2011-08-23 Impact factor: 19.871
Authors: Kimberly Laskie Ostrow; Mohammad O Hoque; Myriam Loyo; Marianna Brait; Alissa Greenberg; Jill M Siegfried; Jennifer R Grandis; Autumn Gaither Davis; William L Bigbee; William Rom; David Sidransky Journal: Clin Cancer Res Date: 2010-06-30 Impact factor: 12.531
Authors: Sheetal Bhan; Sandeep S Negi; Chunbo Shao; Chad A Glazer; Alice Chuang; Daria A Gaykalova; Wenyue Sun; David Sidransky; Patrick K Ha; Joseph A Califano Journal: Clin Cancer Res Date: 2011-05-10 Impact factor: 12.531